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ABSTRACT

Group B Streptococcus (GBS) can be found in the vaginal and genitourinary tract
of females, as well as the genitourinary tract of males, where it behaves as a commensal
organism. However, as an opportunistic pathogen, GBS has the capability to infect the
immunocompromised, making it a major threat to neonates and fetuses. The pathogen can
be passed from mother to baby either in utero or during birth. The capsule, which is a
polysaccharide coating on the outside of the cell, is considered the most important
virulence factor in GBS. Expression of capsule plays a role in evasion of the host
immune response to GBS infection. The presence of capsule on GBS depends on the
CpsA protein, which is involved in the attachment of capsule to the cell wall. CpsA is a
multi-functional protein containing an intracellular domain and two extracellular domains
including the accessory and the LytR domains. Previous data demonstrates a small region
within the accessory domain of CpsA that, when expressed separately, can have a
negative effect on the amount of capsule on the cell. In this study, cell morphology
analysis and capsule assays were used to determine the role of the accessory domain on
CpsA function and capsule production. The data collected in this study suggest that the
accessory domain is important in capsule expression, and without the accessory domain
capsule expression cannot be complemented back to WT CpsA levels. In addition, this
data shows that the intradomain region plays an important, but unknown role in CpsA
function. Finally, for the first time, short chain morphologies were associated with
decreased capsule expression.
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INTRODUCTION

Group B Streptococcus (GBS) can be found in the vaginal and genitourinary tract
of females, as well as the genitourinary tract of males, where it behaves as a commensal
organism. However, as an opportunistic pathogen, GBS has the capability to infect the
immunocompromised, making it a major threat to neonates and fetuses. The pathogen can
be passed from mother to baby either in utero or during birth. The capsule, which is a
polysaccharide coating on the outside of the cell, is considered the most important
virulence factor of GBS [9]. Expression of capsule plays a role in evasion of the host
immune response to GBS infection. The presence of capsule on GBS depends on the
CpsA protein, which is involved in the attachment of capsule to the cell wall [9]. CpsA is
a multifunctional protein containing an intracellular domain and two extracellular
domains including the accessory and the LytR domains [8]. Previous data demonstrates a
small region within the accessory domain of CpsA that, when expressed separately, can
have a negative effect on the amount of capsule on the cell [17]. In this study, the
deletion of the extracellular accessory domain of CpsA will help to determine the role of
this domain on CpsA function and capsule production. Cell morphology analysis, capsule
assays, and virulence studies will all be used to analyze results of a deletion of the
accessory domain.
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Streptococcus agalactiae
Streptococcus agalactiae, commonly referred to as Group B Streptococcus
(GBS), is the leading cause of neonatal infection, premature birth, and stillbirth [20].
Research has suggested that GBS associated infections affect 2,000 live births per year in
the United States [15]. GBS are Gram positive, beta-hemolytic, chain forming cocci that
frequently colonizes the vaginal and genitourinary tract of females and the genitourinary
tract of males [15,20]. They are normal colonizers of the vaginal microflora in 25% of
healthy women, where it behaves as a commensal organism, leaving healthy individuals
unimpacted [20]. However, as an opportunistic pathogen, GBS has the ability to infect
the immunocompromised. The colonization of the vaginal and genitourinary tract of
females makes GBS a serious threat to neonates and fetuses because the pathogen can be
passed down from mother to baby, either in utero or during birth [17]. This pathway

Figure 1. Ascending Group B Streptococcus (GBS) Infection. GBS can be
passed down from mother to baby either in utero or during birth. Ascending
infection during pregnancy involves bacterial colonization of the vagina,
placental membranes, and amniotic cavity which increase the risk of fetal
infection, injury, premature or stillbirths. (Vornhagen, et. al., Trends in
Microbiology. 2017. 25:919-31)
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allows GBS to move from the vagina, to the cervix and into the uterus, where the fetus
can become infected (Figure 1) [17]. In utero, the fetus can aspirate contaminated vaginal
fluid, allowing GBS to cross the blood brain barrier and cause meningitis [5].
Worldwide, it is estimated that 18% of women are colonized, with approximately
22 million pregnant women affected worldwide [18]. A recent meta-analysis performed
in 2015 suggested that there were at least 409,000 maternal, fetal and infant cases of GBS
infection annually [18]. While Africa makes up only 13% of the global population, it
accounts for 54% of the worldwide estimated cases, and 65% of all GBS related fetal and
infant deaths [18]. Early-onset infection is defined as occurring in less than 7 days after
birth and late-onset infection is defined as occurring 7 days or later [20]. The same study
performed in 2015 also estimated 205,000 infant cases with early-onset disease, and
114,000 infant cases with late-onset disease [18]. Early-onset GBS infection is capable of
causing premature and still births and is known to be the leading cause of neonatal
meningitis and sepsis [17]. Other devastating effects of early-onset GBS infection are
encephalopathy and immune impairments which can make it hard to fight other infections
later in life [18]. Even individuals who overcome neonatal GBS infection can still have
neurodevelopmental impairments later on in life [18]. Late onset GBS infection can also
cause hearing and vision loss, learning disabilities, and seizures [18]. Some mothers and
babies can recover from GBS infection, but with a mortality rate of 6%, even if they do
recover there might be some impairments later on in life [18].
The current treatment recommendations for infection prevention in neonates
consists of late gestation screening and intrapartum antibiotic prophylaxis (IAP) [20].
Late gestational screening indicates whether or not a pregnant female is positive for GBS
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infection. IAP is administered intravenously during labor in an effort to prevent the
pathogen from infecting the newborn as it passes through the birth canal. Although IAP is
effective in preventing neonatal infection, the rates of stillbirths and prematurity due to
GBS has not decreased [20]. While these treatments are effective in reducing the
incidence of GBS infection in the first week of life, they are not ideal because treatment
with antibiotics in newborns depletes normal gut flora, which are important in the
development of the immune system [4]. A recent longitudinal study compared the
association of infant antibiotic exposure with childhood health outcomes [2]. This group
found that exposure to antibiotics within the first two years of life was associated with an
increased risk of childhood-onset asthma, allergic rhinitis, atopic dermatitis, celiac
disease, overweight, obesity, and attention deficit hyperactivity disorder (ADHD) [1].
Penicillin was one of the most prescribed antibiotic classes in this study and is also the
standard antibiotic used for IAP in pregnant women, showing the devastating effects of
infant antibiotic use [2]. Recent research also suggests that intrapartum antibiotic
exposure may increase risk of sepsis from other bacteria colonizing the genitourinary
tract [3]. IAP use also affects the mother, potentially increasing the risk of antibiotic
resistance and adverse maternal affects such as allergic reactions [3]. While the use of
IAP is not ideal for mother or baby, its use has doubled in the past 30 years, since no
other ideal treatment options have emerged [3]. Late gestational screening and IAP are
the only current effective treatment for GBS infection in neonates and there is no current
vaccine.
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Virulence Factors of GBS
GBS encodes many virulence factors that aid in its pathogenicity. Some virulence
factors that promote immune evasion include superoxide dismutase, C5a peptidase, serine
protease, and penicillin-binding proteins [11]. Two major virulence factors that play an
important role in GBS dissemination into host cells are pore-forming toxins and sialic
acid containing capsular polysaccharide [11]. Genomic sequencing data has suggested
80% similarity among GBS strains, showing the high conservation of virulence factors
[11].
GBS encodes superoxide dismutase to resist reactive oxygen species from the
host [11]. These enzymes convert superoxide anions to molecular oxygen and peroxide,
which can then be metabolized by other enzymes like catalases or peroxidases [11]. In
order to cleave and inactivate human complement component C5a, GBS encodes a C5a
peptidase [11]. This aids in immune evasion because C5a plays a role in neutrophil
recruitment [11]. Serine proteases cleave the extracellular matrix protein fibrinogen to
fibrin like products, ultimately preventing pathogen recognition and phagocytic uptake of
GBS [11]. Penicillin binding proteins are utilized by bacteria to synthesize peptidoglycan
and resist phagocytosis [11, 20].
Pore-forming toxins are common in many pathogenic bacteria because they allow
the entry of the pathogen into host cells [11]. GBS encodes at least two pore-forming
toxins, which are denoted β-hemolysin/cytolysin (β-H/C) and Christie Atkins Munch
Peterson (CAMP) factor [11]. β-H/C promotes GBS infection by allowing for the
invasion of host epithelial and endothelial cells of the lung and blood brain barrier [11].
This toxin also affects the entire host by promoting liver failure and induced
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inflammatory responses that can cause neurological damage [11]. On the other hand,
CAMP factor is a secreted protein which is known to oligomerize and form small pores
on susceptible target host cells [11]. It is hypothesized that these pore-forming toxins
have compensatory mechanisms in the absence of one of them, which aids in causing a
systemic infection in the host [11].
While the virulence factors described above are all important in immune evasion,
sialic acid rich capsular polysaccharide is understood to be the most important virulence
factor of GBS infection [8]. The capsule of GBS contains sialic acid residues that mimic
host cells (Figure 2). Sialic acids are nine carbon sugars that are also typically found on
glycans of host cells [11]. Utilizing this molecular mimicry, the pathogen evades the
immune system and the host fails to recognize GBS as a foreign substance [11]. As a
result of this evasion, the capsule also prevents complement factor C3b from being
activated and consequently prevents phagocytosis of the pathogen [11].

Capsule in Streptococcal Species
GBS is not the only Streptococcal species that requires capsule for survival in
host epithelial cells. The capsule operon is highly conserved among Streptococcal species
and other Gram-positive organisms [7]. The first gene on this locus is the cpsA gene,
which encodes one of the transcriptional regulators of the capsule operon, the CpsA
protein [7]. The CpsA protein is understood to directly aid in the production of capsule
and virulence of the bacteria [8]. This protein has been the main focus of much of the
research regarding capsule expression and production in Gram positive organisms and is
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the focus of the GBS research being performed in the Neely lab at the University of
Maine.
In Streptococcus
pneumoniae and Streptococcus
suis, the presence of capsule
had a significant effect on the
minimal bactericidal activity of
many cell wall reactive agents
[6]. The first four genes of the
capsule operon in S. iniae and
Figure 2. Electron micrograph of the capsular polysaccharide
of Group B Streptococcus. (F.D. Xia, et. al. (2015). Microbes
and Infection 17. 71-76.)

GBS have 70% amino acid
similarity, suggesting that CpsA

is highly conserved as a control mechanism for virulence in Streptococcal species [8].
This observation suggests that capsule is mediated by the CpsA protein [6]. Further
research demonstrates that the purified CpsA protein specifically binds to the capsule
promoter region of DNA [8].
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Figure 3. Percent zebrafish survival after 7 days post injection. Media was used as a negative
control and 100% of zebrafish survived after 7 days post injection. In the CpsA mutant GBS and S.
iniae, 40% of zebrafish died after 7 days post injection. In the GBS and S. iniae WT, 100% of
zebrafish died after 7 days post injection. This data indicates that the mutant CpsA strains of
Streptococcal species are less virulent than WT strains, suggesting that CpsA is an important
virulence factor for infection. (Neely Laboratory).

Streptococcus iniae, a zoonotic pathogen that is able to infect both animals and
humans, also contains the CpsA protein. Previous research of S. iniae infection in
zebrafish showed that CpsA mutants were more susceptible to phagocytosis than WT,
confirming that CpsA plays a role in capsule production and thus virulence (Figure 3) [9].
In this study, small doses of WT S. iniae were injected into the dorsal muscle of adult
zebrafish. This induced infection resulted in a high mortality rate and large bacterial
burden [9]. Injection of CpsA mutant S. iniae reduced lethality, however, and there was
no increase in bacterial burden, suggesting that the mutated CpsA protein decreases the
virulence of GBS [9]. This research summarizes that bacterium-phagocyte interaction are
different between the WT and CpsA mutant, suggesting that WT is pathogenic, and the
CpsA mutant is non-pathogenic, confirming its clinical relevance in the treatment of GBS
infection [9]. The capsule of S. iniae is closely related to GBS, suggesting that these data
may be generalized to include GBS [9].
8

CpsA Protein of GBS
CpsA has an intracellular N-terminal domain, three transmembrane domains, and
an extracellular domain, including the C-terminal domain (Figure 4). The extracellular
portion of the protein is broken into two domains, the accessory and LytR domains [9].
These two domains are connected by an intradomain region of uncharacterized structure
and function. The extracellular domains of CpsA are known to fold separately and have
separate functions (Figure 5) [9]. While the CpsA protein is a member of the
LytR_CpsA_Psr protein family, it has several differences compared to other members of
the family [8]. The CpsA protein is the only member of its family that possesses an
extracellular accessory domain, and it also has three transmembrane domains instead of
one [12].

Figure 4. CpsA protein topology embedded within the cell membrane, including the N
terminus, three transmembrane domains, two extracellular domains, and C terminus. (No
citation, made by me)

Intracellular CpsA Domain
The intracellular N-terminal domain of CpsA is a small, cytoplasmic region that is
highly conserved in both GBS and other Gram-positive organisms [8]. While the
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complete function of this domain is not understood, research suggests that it does contain
a DNA binding region [8]. The high density of positively charged amino acids allows this
region to bind its own promoter, attracting the negatively charged backbone of DNA to
bind [8].
Previous research on the intracellular domain of the CpsA proteins of S.
pneumoniae and GBS suggests that there is a leucine zipper domain which extends into
the transmembrane region and is commonly associated with DNA binding through
dimerization [6]. Regardless of the similarity between the intracellular domains of GBS
and S. pneumoniae, no data has supported similarity between these regions of S. iniae and
GBS, suggesting the need for further research of this leucine zipper motif [6]. Although
there are genomic differences between this region in Streptococcal species, the GBS and
S. iniae CpsA proteins do bind DNA in vitro, however, the mechanism is unknown [7].

Extracellular Domains
The focus of this research is understanding how the accessory domain of CpsA
affects capsule production and expression. It is important to understand the structure of
the accessory and LytR domains of CpsA and how they function extracellularly because
CpsA is the only protein in its family that carries the accessory domain. As mentioned
previously, these domains fold separately and have separate functions (Figure 5) [12].
This data suggests many alpha helices in each domain, as well as an active site in the
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LytR domain [12]. This region shows little structural homology to any other protein, only
having 11% sequence identity with an uncharacterized peptide binding protein [12].

Figure 5. Crystal structure of the extracellular domains of CpsA in
S. pneumoniae. D1 represents the accessory domain and D2
represents the LytR domain, which are connected by an
intradomain region. (Kawai, et. al. EMBO Journal. 2011. 49314941)

GBS CpsA is unique in that it is the only member of the protein family which
possesses an extracellular accessory domain which has no homology to any other protein
domains [17]. While no previous research has deleted the accessory domain, one study
suggested that, in the absence of the LytR domain, the extracellular accessory domain
decreases capsule production and cell wall integrity [17]. This mutation causes a
dominant negative effect, where the mutation interferes with the wild type form of the
protein [17]. A dominant negative effect occurs extracellularly when the accessory
domain interferes with normal mechanisms of cell wall integrity and capsule production
[17]. It has been hypothesized that specific conformations of CpsA might allow the
accessory domain to negatively impact CpsA binding interactions, thus decreasing
capsule production and cell wall synthesis [17]. Overall, this dominant negative effect
11

indicates that the accessory domain plays an important role in virulence, whether it is
capsule dysregulation or cell wall instability remains unknown [17]. The production of a
dominant negative effect is of clinical importance in the treatment of GBS infection.
Much of the function and mechanisms of the accessory domain are not understood,
suggesting the need for further research to determine its implications in capsule
production and GBS virulence.
Previous research performed on the extracellular domains of CpsA focused on the
LytR domain, leaving the function and mechanism of the accessory domain largely
unknown. Much of this research was also studied in Streptococcal species other than
GBS, as well, making the specific mechanisms of these domains in GBS unknown as
well. Previous research on the LytR domain, however, suggests that it aids in the
attachment of cell wall carbohydrates, capsule, and teichoic acids to the cell wall [17].
Carbohydrate precursors are first made on the inner leaflet of the bacterial membrane,
then the outer membrane, where it is hypothesized that the LytR domain acts as a ligase,
attaching the precursors on the cell wall [17].
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Figure 6. A) Buoyant density measurements of capsule expressed by full and truncated GBS CpsA
proteins. B) Full length GBS CpsA protein. C) ∆LytR truncated GBS CpsA protein. D)
∆IntracellularDomains, ∆TransmembraneDomain, ∆LytR truncated GBS CpsA protein. (Neely lab)

Previous research performed in the Neely lab suggests that the accessory domain
has some function independent of the LytR domain (Figure 6). In this study, a buoyant
density assay was performed in order to determine the buoyancy of cells based on a sugar
gradient which is directly correlated to capsule expression. Figure 6 displays the
measurements of capsule expressed by both full and truncated versions of GBS CpsA.
The first four bars were used as controls and the last two bars were the experimental
samples. The first sample shows WT GBS and an empty vector, displaying the standard
13

amount of capsule expressed. The second bar shows the deletion of CpsA with an empty
vector, showing how much less capsule is produced when CpsA is deleted from GBS.
When compared to the WT + vector sample, approximately half as much capsule is
expressed when CpsA is deleted. The third bar displays the deletion of CpsA with the full
CpsA protein expressed on a plasmid, showing how much capsule production can be
complemented back with CpsA from a plasmid. When compared to the WT + vector
sample, almost all of the capsule is complemented back with CpsA from a plasmid. The
fourth bar displays WT GBS and the deletion of the LytR domain expressed from a
plasmid and shows the effect of capsule production if the extracellular domain is
truncated. When compared to the WT + vector sample, less capsule is expressed,
indicated the dominant negative effect of this mutation, because the WT CpsA is still
present on the chromosome. Therefore, the presence of the truncated CpsA can override
the function of the WT full length protein. The fifth bar displays the deletion of the first
and second transmembrane domain, intracellular domains, and the LytR domain, leaving
just the third transmembrane domain and the accessory domain remaining and expressed
from a plasmid in the WT strain (WT CpsA still present). This data shows that when
DNA binding domains were removed, capsule production was approximately the same as
the WT + ∆LytR capsule production, supporting the hypothesis that inhibition of capsule
production is due to the extracellular domain, not the intracellular domains. Finally, the
sixth bar shows the CpsA deletion mutant GBS with the truncated CpsA (accessory
domain and third transmembrane domain) expressed from a plasmid. When compared to
the ∆CpsA + CpsA data (third bar), the data suggests that this truncated version of CpsA
cannot complement back the amount of capsule production. All of this data taken
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together suggests that the accessory domain functions independently of the LytR and
intracellular domains, inhibiting capsule production in some way.

Research Goal
The polysaccharide capsule of GBS is suggested to be the most important
virulence factor in GBS infection [8]. The sugar coating the outside of the cell wall is
decorated in sialic acid residues which mimic host cells, aiding in immune evasion [21].
Because of this molecular mimicry, GBS is able to target and colonize different parts of
the body, including the spleen, heart, and brain, making it the leading cause of neonatal
meningitis and sepsis [20]. It is of clinical relevance to understand the mechanisms of
dissemination used by GBS and other human pathogens to survive in various
environments, such as the epithelium of the vaginal tract [7]. Because of the function of
capsule, it is important to understand its interactions in the human body in order to further
antimicrobial therapy [3].
The goal of this research study is to alter part of the CpsA protein of GBS in order
to determine its function. The region of interest is the accessory domain of the CpsA
protein. The CpsA protein belongs to the LytR-CpsA-Psr protein family, which is known
to act as a ligase, attaching the capsule to the cell wall. The CpsA protein is the only
protein in this family that has an extracellular accessory domain, but the specific function
of the accessory domain remains unknown. This research study aims at determining the
function of the accessory domain of the CpsA protein through its deletion and to
determine the virulence of GBS with the ∆AccessoryDomain mutation.
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MATERIALS AND METHODS

Digestion
The plasmid pLZ12-rofA-pro (strain #12E34) was digested with BamHI and
incubated at 37ºC for 15 minutes. Then, the plasmid was digested again with PstI and
incubated at 37ºC for 30 minutes and was then moved to 80ºC for 5 minutes to inactivate
the restriction enzymes. The digested plasmid was separated on a 0.8% agarose gel to
check for a band at 4500 bp. GeneJet Gel Extraction Kit (ThermoFisher) was used to
isolate the plasmid from the gel.

Figure 7. plZ12-rofA-pro plasmid map. Mutant strains of CpsA
were inserted into the plasmid using BamHI and PstI restriction
sites. Chloramphenicol was used as a selectable marker for positive
transformants. repR is an initiator protein which allows the plasmid
to be expressed at a low copy number. (Image created using
BioRender)

Polymerase Chain Reaction (PCR)
Streptococcus agalactiae genomic DNA was used as a template to amplify the
cpsA gene region. A high-fidelity DNA polymerase, Q5 (New England Biolabs), was
16

used and the primers were specific to each reaction. The long fragment (Reaction 1,
Figure 8) used primers 5’ GBS-CpsA-RBS-BamHI and 3’ GBS-CpsA-∆AD (#1740,
#1903). The short fragment (Reaction 2, Figure 8) used primers 3’ GBS-CpsA-full-PstI
and 5’ GBS-CpsA-∆AD (#1672, #1902). PCR was performed using a Thermocycler at an
annealing temperature of 68ºC. Both reactions were separated on 0.8% agarose gel to
confirm fragments of ~300bp and ~1178bp. Both reactions were gel purified using the
GeneJet Gel Extraction Kit (ThermoFisher).

PCR Splice Overlap Extension (SOE)
The two PCR fragments created were used as a template to SOE the fragments
together, forming a full-sized fragment of ~1000 bp. Q5 DNA Polymerase (New England
Biolabs) and primers #1672 and #1740 were used at an annealing temperature of 65ºC.
The reaction was separated on a 0.8% agarose gel to confirm the final full-sized
fragment. The full-sized fragment was gel purified using the GeneJet Gel Extraction Kit
(ThermoFisher), followed by digestion with BamHI and PstI.

Ligation
The digested PCR SOEing fragment was inserted into the plasmid using T4 DNA
ligase (New England Biolabs). The reaction was incubated at 37ºC for 30 minutes.
Butanol and ethanol precipitations were performed to prior to electrotransformation.
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Figure 8. PCR SOEing model. The full protein contains the three transmembrane domains and
both extracellular domains, the accessory and LytR domains. The truncated protein shows the
deletion of the accessory domain, containing the three transmembrane domains and the LytR
domain. Reactions 1 and 2 were used to delete the accessory domain of CpsA, and reaction 3
was used to SOE the fragments together to create the ∆AccessoryDomain CpsA fragment.

Transformation into E. coli
The ligation reaction was mixed with electro-competent cells and transferred to
cold electroporation cuvettes (Figure 9). The cells were electroporated with a Gene Pulser
(BioRad), with settings at 25 µF, 2.5 kV, and 200 Ω. Immediately after electroporation,
the cells were transferred to SOC medium and incubated at 37ºC for 90 minutes with
continual shaking. Cells were then plated onto Luria-Bertani (LB) agar plates
supplemented with chloramphenicol (cam) at a final concentration of 15 µg/mL final
18

concentration. Plates were incubated at 37ºC overnight. Several transformants were
purified on fresh LB-Cam plates. PCR of several purified transformants was performed to
confirm the proper insertion of the PCR SOEing fragment.

Figure 9. Electrotransformation of plZ12-rofA-pro plasmid DNA into E. coli. (Image created with
BioRender.com)

Colony PCR
To confirm the proper insertion of the cpsA gene on the plasmid in E. coli, colony
PCR was performed. The outside primers (#1672, #1740) were used to amplify the final
fragment in the plasmid and then visualized by electrophoresis.

Plasmid Isolation
An overnight culture of a confirmed positive transformant was grown at 37ºC in a
shaking incubator overnight in a 250 mL Erlenmeyer flask with 100 mL of LB broth
supplemented with 15 µg/mL chloramphenicol. The next day, a PureLink HiPure Plasmid
19

Filter DNA Purification Kit (Invitrogen) was used to purify plasmid DNA. Isopropanol
and ethanol precipitation were performed, and a Nanodrop (ThermoFisher) was used to
determine the concentration of the isolated DNA. The plasmid insert was sequenced to
confirm that the construct was correct and that no mutations were created by PCR.

Transformation into GBS
GBS515 cultures were grown statically in THY B (Todd-Hewitt-Yeast Broth)
supplemented with 80 mM glycine overnight at 37ºC in a shaking incubator. A 1:20
dilution (1.25 mL) of the culture in 25 mL of THY B supplemented with 80 mM glycine
the following day. The subculture was grown to an OD600 of 0.4 and harvested by
centrifugation. The cells were washed and resuspended with 10% glycerol. Cells were
then transferred to a cold electroporation cuvette. The isolated plasmid was added to the
cold cuvette. The cells were electroporated with a Gene Pulser (BioRad), with settings at
25 µF, 2.0 kV, and 400 Ω (Figure 10). Immediately after electroporation, cells were
transferred to THY B medium and incubated at 37ºC for 90 minutes with continual
shaking. Cells were then plated on THY B supplemented with chloramphenicol at a final
concentration of 3 µg/mL. Cells were transformed into both WT and ∆cpsA GBS strains.
Plates were incubated overnight at 37ºC.
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Figure 10. Electrotransformation into GBS. The plZ12-rofA-pro plasmid was isolated from E. coli
and transformed into GBS using an electroporation protocol. (Image created with BioRender.com)

Enzyme-linked immunosorbent assay (ELISA)
Strains were grown in THY B-Cam3 broth at 37ºC overnight. Cultures were
normalized to an OD600 of 0.75, pelleted, and washed three times with Tris-buffered
saline + Tween (TBST). Primary antibody (rabbit anti-Serotype 1a GBS) was diluted to
1:20,000. Secondary antibody (secondary goat, anti-rabbit IgG conjugated to alkaline
phosphatase [AP]) was diluted to 1:5,000. Secondary antibody was pre-absorbed to
prevent nonspecific binding using both ∆cpsA and WT GBS strains. Cells were incubated
with 1 µL primary antibody at 4ºC for 1 hour with rocking before being washed three
more times with TBST. Cells were then incubated with secondary antibody for 1 hour
with rocking at 4ºC before being washed three more times with TBST. Cells were
resuspended in TBST and transferred to a 96-well plate. Alkaline phosphatase activity
was measured after a 1 hour incubation in the dark at 37ºC after addition of p-nitrophenyl
phosphate substrate (Sigma) (Figure 11). OD405 and OD600 were used to calculate AP
activity and cell growth, respectively. Each sample was done in triplicate at a 1:1, 1:2,
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and 1:4 dilution. Each experiment was repeated three times. Alkaline phosphatase (AP)
units were calculated using the following equation:
𝐴𝑃 𝑈𝑛𝑖𝑡𝑠 =

𝑂𝐷!"#
∗ 1000
𝑉𝑜𝑙 ∗ 𝑇 ∗ 𝑂𝐷$""

Vol = culture volume in well
T = time of incubation with substrate

Figure 11. Enzyme-linked immunosorbent assay
(ELISA) can be used to measure the amount of
capsule on the cell. A) A primary antibody to the
capsule is recognized by a secondary antibody,
conjugated to alkaline phosphatase (AP). B) Plate
of ELISA reactions. The wild type GBS will
express a yellow color due to the presence of
capsule. The ∆cpsA GBS will show a pale-yellow
color due to the amount of capsule. The result of
∆AccessoryDomainCpsA GBS is unknown. (No
citation, made by me)

Chain Length Analysis
Overnight cultures of all strains were grown statically at 37ºC in THY B medium.
Using 7 µL of the overnight culture, wet mount slides were made and visualized with a
Zeiss Axioskop compound microscope. Multiple images of each strain were documented,
and the length of each chain was counted and analyzed.
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Cell Aggregation Assay
Overnight cultures of all strains were grown statically in clear, round bottom
tubes at 37ºC in THY B medium with antibiotics. Following 48 hours of growth, the
suspension of the cultures in the tubes were documented.
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RESULTS
Plasmid Construction
Plasmid construction was
carried out as described in the
materials and methods. Following
plasmid construction, PCR was
performed to create truncated
versions of the fragment of sizes
~3000 bp and ~1178 bp. After gel
purification, PCR SOEing was
performed to form a truncated
fragment of ~1000 bp. The fulllength fragment was then digested
and ligated before transforming into
E. coli. Positive transformants were
selected via colony PCR and DNA

Figure 12. Gel electrophoresis of colony PCR shows
positive colonies with a band at ~1470 bp. Positive
colonies were those that included a successful
deletion of the accessory domain, resulting in a
fragment of ~1470 bp.

was isolated and used to transform into GBS after sequencing to confirm the correct
mutation (Figure 12).
In this study, six different strains of GBS were constructed in order to compare
the effects of a deletion of the accessory domain, both with and without the intradomain
region remaining (Figures 13,14). In strains that have WT background, WT CpsA was on
the chromosome and expressed in addition to what was expressed on the plasmid (Figure
14). In strains that have ∆CpsA background, the only CpsA expressed was from the
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plasmid (Figure 14). Both the WT GBS and ∆CpsA GBS expressed either an empty
vector, or a plasmid expressing WT CpsA, ∆Acc+ CpsA, or ∆Acc- CpsA (Figures 1417). The ∆Acc+ CpsA included the intradomain region, while the ∆Acc- CpsA did not
include the intradomain region (Figure 13).

Figure 13. Comparison of WT CpsA to the truncated versions used in this study. A) Full length
CpsA protein. B) ∆Acc+ CpsA, where the three transmembrane domains, intradomain region, and
LytR domain remain, with a deletion of the accessory domain. C) ∆Acc- CpsA, where the three
transmembrane domains and LytR domain remain, with the deletion of the accessory domain and
intradomain region. (No citation, made by me)
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Figure 14. Construction of all 6 strains used in this study. WT GBS and ∆CpsA GBS expressing an
empty vector, ∆Acc+ CpsA, or ∆Acc- CpsA on a plasmid. (Image created with BioRender.com)

Figure 15. WT GBS and ∆CpsA GBS expressing the empty vector on a plasmid. (Image created
with BioRender.com)
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Figure 16. WT GBS and ∆CpsA GBS expressing ∆Acc+ CpsA on a plasmid. (Image created with
BioRender.com)
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Figure 17. WT GBS and ∆CpsA GBS expressing ∆Acc- CpsA on a plasmid. (Image created with
BioRender.com)
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Chain Length Analysis
Previous research examined the relationship between chain length and cell wall
integrity [7]. The data shows that WT strains express shorter chains of cocci, 2-6 cocci per
chain, and ∆CpsA strains express much longer chains of cocci, up to 20 cocci per chain
[7]. Long chain morphologies have been associated with less capsule expression [7]. In this
study, researchers treated all GBS strains with a subinhibitory amount of lysozyme and
compared the chain lengths between the treated and untreated strains [7]. Lysozyme has
enzymatic activity that cleaves specific residues of the peptidoglycan cell wall.
Specifically, it has muramidase activity which cleaves the N-acetyl-D-glucosamine
residues of the peptidoglycan cell wall [7]. After growing in the presence of lysozyme, all
cells existed as either diplococci or single cocci in both the WT and ∆CpsA strains [7].
This data suggests that CpsA dependent changes to the cell wall may be responsible for the
observed chain length variances [7].
To determine the differences in morphology between the different GBS strains
examined in this study, 10 images of each strain were visualized and documented using
light microscopy at 1000X magnification using a Zeiss Axioskop compound microscope
(Figure 18). The number of cocci in each GBS chain was counted and recorded. The
average cocci per chain was determined for each GBS strain (Table 1). Overall, the
∆CpsA mutant strains had longer chain lengths relative to the WT strains. When
compared to the WT-vector, ∆CpsA-vector expressed slightly longer chains. The average
chain length in the WT-vector strain was 1.784 cocci, while the average chain length in
the ∆CpsA-vector strain was 3.26 cocci (Table 1). The ∆CpsA-vector strain also showed
slightly more distribution in chain length than the WT-vector strain (Figures 19, 20).
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When compared to the WT-∆Acc+ strain, the ∆CpsA-∆Acc+ strain expressed much
greater variation in chain length (Figures 21, 22). The average chain length of the WT∆Acc+ strain was 1.897 cocci per chain, while the average length of the ∆CpsA-∆Acc+
strain was 6.35 cocci (Table 1). The majority of the chains in the WT-∆Acc+ strain were
between 1-4 cocci per chain, but the ∆CpsA-∆Acc+ strain expressed much greater
variation in chain length, with a range from 1 cocci per chain to 23 cocci per chain
(Figures 21, 22, Table 1). When compared to the WT-∆Acc- strain, the ∆CpsA-∆Accstrain expressed longer chain lengths (Figures 23, 24). The average chain length for the
WT-∆Acc- strain was 1.843 cocci, while the average chain length for the ∆CpsA-∆Accstrain was 4.059 cocci (Table 1). The ∆CpsA-∆Acc- strain also expressed more
distribution in chain length, with a range from one cocci per chain to 23 cocci per chain.
The majority of the chains in the WT-∆Acc- strain were between 1-4 cocci per chain
(Figure 23). When each strain was compared to one another, the WT-V strain showed the
least variation, while the ∆CpsA-∆Acc+ strain expressed the most variation in chain
length and the longest chains (Figure 25).

Table 1. Maximum, minimum, and average chain length of each sample documented in the chain
length analysis.
WT-V

∆-V

WT-∆Acc-

∆-∆Acc-

WT-∆Acc+

∆-∆Acc+

Maximum

10

20

13

23

23

23

Minimum

1

1

1

1

1

1

1.784

3.26

1.843

4.059

1.897

6.35

Average
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Figure 18. Images taken for chain length analysis using compound microscopy. A) WT-Vector. B)
∆CpsA-Vector. C) WT-∆Acc+. D) ∆CpsA-∆Acc+. E) WT-∆Acc-. F) ∆CpsA-∆Acc-.
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Figure 19. Chain length analysis of WT-Vector strain. (Image created with BioRender.com)
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Figure 20. Chain length analysis of ∆CpsA-Vector strain. (Image created with BioRender.com)
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Figure 21. Chain length analysis of WT-∆Acc+ strain. (Image created with BioRender.com)
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C.

Figure 22. Chain length analysis of ∆CpsA-∆Acc+ strain. (Image created with BioRender.com)
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Figure 23. Chain length analysis of WT-∆Acc- strain. (Image created with BioRender.com)
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Figure 24. Chain length analysis of ∆CpsA-∆Acc- strain. (Image created with BioRender.com)
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Figure 25. Chain length comparison between each strain of GBS.

Cell Aggregation Assay
Cell aggregation assays were performed according to materials and methods to
examine the difference in culture growth in WT and ∆CpsA GBS strains. Upon
examination of culture tubes, WT strains exhibited more turbidity than ∆CpsA strains,
which exhibited more clearing (Figure 26). Each strain of WT and ∆CpsA GBS were
compared against one another. In each strain, the ∆CpsA GBS exhibited less turbidity
than its WT GBS counterpart. One strain, ∆CpsA-∆Acc-, looked similar to WT-∆Acc-,
which could have likely been due to a disruption of the cell pellet. Although this could be
an error, the ∆CpsA-∆Acc- strain still exhibited slightly more clearing than the WT∆Acc- strain.
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Figure 26. Comparison of cell aggregation of all six strains created in
this study. A) WT-Vector. B) WT-∆Acc+. C) WT-∆Acc-. D) ∆CpsAVector. E) ∆CpsA-∆Acc+. F) ∆CpsA-∆Acc-.

ELISA
An enzyme-linked immunosorbent assay (ELISA) was used to determine capsule
expression. The amount of alkaline phosphatase (AP) units in each sample is directly
correlated to the amount of capsule expressed by the cell. The AP units were calculated
using the following equation:
𝐴𝑃 𝑈𝑛𝑖𝑡𝑠 =

𝑂𝐷!"#
∗ 1000
𝑉𝑜𝑙 ∗ 𝑇 ∗ 𝑂𝐷$""

Vol = culture volume in well
T = time of incubation with substrate
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ELISA was performed in triplicate in order to determine reproducibility of results. After
three trials, AP units of each trial were averaged together (Figure 27). Standard error and
significance values were determined (Figure 27).
When comparing WT-Vector and ∆CpsA-Vector strains, ∆CpsA-Vector is not
able to complement back the same amount of capsule as WT-Vector (Figure 27).
Calculated p-values suggest that there is significant difference between these strains.
When comparing the WT-mutant CpsA strains to the WT-Vector, the WT-∆Acc+
strain was able to complement back approximately the same amount of capsule as the
WT-Vector strain, but WT-∆Acc- could not do the same (Figure 27). Calculated p-values
suggest that there is a significant difference between the WT-Vector and WT-∆Accstrains, but there was no significant difference between WT-Vector and WT-∆Acc+
strains (Figure 27). These p-values are consistent with the data shown in Figure 27.
When comparing the ∆CpsA-mutant to the ∆CpsA-Vector, both the ∆CpsA∆Acc+ and ∆CpsA-∆Acc- strains were able to complement back approximately the same
amount of capsule as the ∆CpsA-Vector (Figure 27). Calculated p-values suggest that
there is no significant difference between these strains, and this is consistent with the data
shown in Figure 27.
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Figure 27. Average ELISA data to determine capsule expression. There is a significant
difference between WT-Vector and WT-∆Acc- strains (p=0.03522) and between WT-∆Acc+ and
WT-∆Acc- strains (p=0.03607). No significant difference was found between WT-Vector and
WT-∆Acc+ strains (p=0.9). There is a significant difference between WT-Vector and ∆CpsAVector strains (p=0.0250), but no significant difference between any of the ∆CpsA strains. Pvalues were determine using a one-way ANOVA procedure including a Tukey Test.
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DISCUSSION

S. agalactiae, also known as Group B Streptococcus (GBS), is a commensal
organism that colonizes the vaginal and genitourinary tract of females, where it can act as
an opportunistic pathogen in the immunocompromised, such as neonates and fetuses [17].
GBS is a widespread pathogen that affects over 22 million pregnant women worldwide,
with approximately 320 million infant GBS cases as of 2015 [4]. In the United States
alone, GBS is responsible for approximately 900,000 infections, with a mortality rate of
6% in neonates and infants [17]. GBS infection is known to be the leading cause of
neonatal meningitis, and it can also cause other implications, such as septicemia,
premature birth, and stillbirth [20]. This pathogen can be passed from mother to baby,
either in utero or during birth, posing a serious threat to neonates and fetuses [17].
Because of this threat, pregnant women undergo late gestational screening in
order to prevent the spread of infection. If the pregnant woman is a colonizer of GBS,
intrapartum antibiotic prophylaxis (IAP) is administered intravenously during delivery
[20]. While this treatment is effective at reducing the incidence of GBS infection within
the first few weeks of life, the long-term effects of antibiotic use in newborns can be
devastating. A recent study linked antibiotic use in the first two years of life with a higher
risk of celiac disease, childhood onset asthma, allergic rhinitis, atopic dermatitis,
overweigh, obesity, and ADHD [2]. Therefore, the need for improved, specific treatment
for GBS infection in neonates is of the utmost importance.
The most important virulence factor of GBS infection is known to be the capsular
polysaccharide [8]. The capsule has been a novel target for the treatment of GBS
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infection. In GBS, capsule is dependent upon the CpsA protein, which is encoded by the
cpsA gene. This protein acts as one of the transcriptional regulators of the capsule operon
and is a multifunctional protein containing an intracellular DNA-binding domain, 3
transmembrane domains, and two extracellular domains, the LytR and accessory domains
[6]. Crystal structure of the extracellular domains suggests that they fold separately and
have separate functions [12]. The CpsA protein is highly homologous among
Streptococcal species, such as S. iniae, S. pneumoniae, and S. suis [6,8]. Previous
research suggests that the CpsA protein directly aids in the production of capsule and
thus, the virulence of GBS [7]. Since capsule is required for GBS survival in the
bloodstream, understanding the mechanisms of dissemination used by GBS to survive in
tissue environments, such as the vaginal epithelium, is of crucial importance.
Prior research performed in the Neely lab compared percent zebrafish survival
over days post injection of WT and mutant GBS and S. iniae (Figure 3). This data
demonstrated that the mutant strains were less virulent, reducing the lethality of infection
by approximately 60%, compared to the WT strains where 100% of zebrafish died after 7
days post injection. This data suggested that CpsA plays an unknown, but important role
in virulence of GBS.
Much of the previous CpsA research has focused on the LytR domain, however
no previous research has analyzed the effect of a deletion of the accessory domain. The
goal of this study was to determine the role of the accessory domain on CpsA function
and capsule production in GBS by deletion of the accessory domain and then analysis of
the mutated CpsA using a series of virulence assays. The accessory domain was
successfully deleted through plasmid construction and electrotransformation, first into E.
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coli, and then into GBS. Once the mutant strain was transformed, chain length analysis
was performed to determine the effect of mutant CpsA on chain length morphology.
Prior studies have suggested that WT GBS strains express shorter chains of cocci
compared to ∆CpsA GBS strains, which are known to express longer chains of cocci due
to decreased capsule expression. In this study, when WT CpsA was expressed on the
plasmid, chains of cocci were shorter than compared to that of the ∆CpsA strains, on
average (Table 1). This data is consistent with the findings of the chain length analysis
performed in this study, however, these results provide new information about chain
length. Interestingly, there was a difference in chain length between the ∆Acc+ and
∆Acc- mutant strains expressed on both WT and ∆CpsA plasmids, suggesting that the
intradomain region has some effect on chain length. No previous research has deleted
both the accessory domain and intradomain region from CpsA. The intradomain region
connects the accessory domain and LytR domain and is 180 bp in length (60 amino
acids). While this is a small fragment of CpsA, the results of the chain length analysis
suggest that this region could play an important role in GBS virulence. Future studies
should perform the same chain length analysis on WT-WT and ∆CpsA-WT strains as an
additional control in order to fully understand the impact of mutant CpsA on chain length
phenotypes.
An ELISA was used to determine the difference in capsule presence on the cell
between each strain in this study. In previous analyses, long chain phenotypes have
correlated to less capsule expression [7]. This is consistent with the data collected in this
study, where the ∆CpsA-∆Acc+ and ∆CpsA-∆Acc- strains expressed the longest chains
of cocci and expressed the lowest amount of capsule (Figures 22, 24, 27). Interestingly,

44

the WT-Vector strain looks phenotypically similar to the WT-∆Acc+ and WT-∆Accstrains, even though the capsule expression between the three strains varied significantly.
All three WT strains expressed similar chain lengths, with approximately 85% of those
samples being 1-2 cocci per chain. However, the WT strains expressed different capsule
levels, with WT-V and WT-∆Acc- being statistically significant from one another.
Based on the ELISA data, the WT-∆Acc- strain showed less capsule than the WTVector strain, even though WT CpsA was expressed from the chromosome. This suggests
that the WT-∆Acc- strain causes a dominant negative effect because this mutation is
interfering with the normal function of CpsA (Figure 27). The expression of only the
LytR domain on both the vector and plasmid in the WT-∆Acc- strain is inhibiting capsule
expression in some way. The WT-∆Acc+ strain does not cause a dominant negative
effect, however, because this strain is able to complement back approximately the same
amount of capsule expressed by the WT-Vector (Figure 27). Furthermore, the difference
in capsule expression between the WT-∆Acc- and WT-∆Acc+ strains suggests that the
intradomain region plays an important, but unknown role. This data is interesting, since
no previous work has studied the effect of the intradomain region on capsule expression
in GBS CpsA.
A cell aggregation assay was performed in order to determine the difference in
bacterial culture suspension between each strain. When comparing all six strains overall,
the WT GBS strains exhibited more turbidity than the ∆CpsA GBS strains (Figure 26).
Each WT GBS strain was also compared against its ∆CpsA GBS counterpart (Figure 26).
In each strain, the WT GBS expressed more turbidity than the ∆CpsA GBS strain. In
addition, the ∆CpsA GBS strains showed a slightly larger cell pellet than the WT GBS
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strains. This difference in turbidity and cell pellet size is likely due to the decrease in
capsule that is caused by the deletion of CpsA. When CpsA is not present, it is
understood that there is a decrease in capsule and an increase in chain length, which
causes the cells to be less buoyant and, thus, sink more towards the bottom of the tube,
causing both a larger cell pellet and less turbidity.
HHpred is a bioinformatics toolkit that aligns amino acid sequences to determine
protein homology and predict structure. Previous HHpred data analysis showed no
protein homologies to the accessory domain of the CpsA protein, until April 2021. The
most recent data observed via HHpred suggests that the accessory domain has homology
with substrate binding proteins (Figure 28). These proteins are mostly amino acid binding
transport proteins, including sensory transduction histidine kinase, periplasmic binding
transport proteins, glutamate receptors, and ABC transporters (Figure 29) [HHpred]. This
data suggests that CpsA is homologous to a periplasmic L-aspartate/L-glutamate binding
protein (DEBP) from Shigella flexneri [HHpred]. Previous data suggests that this protein
acts as a periplasmic binding protein (PBP) of the ATP-binding cassette (ABC) transport
system [10]. The PBP aids in transport by trapping the ligand that diffuses through the
outer membrane into the periplasmic space of bacteria [10]. Further characterization of
both proteins needs to be performed in order to determine the structural and functional
homology between the two.
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A.

B.

Figure 28. A) Alignment of WT CpsA showing homology to other proteins. B) Amino acid alignment
of WT CpsA with a periplasmic binding transport protein, showing 97.69% probability. (Images from
HHpred)
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CONCLUSIONS

While previous studies have deleted the LytR domain of CpsA, none have deleted
the accessory domain or intradomain region. These studies have suggested that when
there is a deletion of the LytR domain, significantly less capsule is expressed. This data
led to the conclusion that the LytR domain is the important in the attachment of capsule
to the cell wall, acting as a ligase. The accessory domain does, in fact, play a role in
capsule expression and chain length. The data collected in this study from ELISA data
suggests that the LytR domain cannot do this alone, and that the accessory domain is also
required. The accessory domain might be involved in this process initially, by picking up
the polysaccharide and handing it over to the LytR domain for further attachment.
Furthermore, the intradomain region might also have a role in capsule attachment to the
cell wall. The intradomain is important because there are differences between strains that
express and do not express this region.
These conclusions come with some caveats, however. This data has not shown
that when the protein is expressed from a plasmid that it is actually placed in the
membrane. Since this study has suggested a dominant negative effect, CpsA most likely
does make it to the membrane, but further experiments would need to be designed and
analyzed to monitor the placement of the protein in the membrane. In addition, the ∆Accstrains are missing the 60 amino acid intradomain region which allows the LytR domain
to be closer to the membrane itself. The WT-∆Acc- strain caused a dominant negative
effect, suggesting that the LytR domain might not be able to function correctly, without
the intradomain region being present.
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FUTURE DIRECTIONS

There are still many more assays that need to be performed in order to determine
the role of the accessory domain on CpsA function and capsule production in GBS. These
experiments include fluorescent vancomycin assays, Western blots, and virulence studies
using zebrafish as a model organism.
Fluorescent vancomycin assays can be used to determine the cell wall integrity of
modified CpsA. In this experiment, newly modified cell walls in the samples are tagged
with fluorescent vancomycin stain and observed with confocal microscopy. This allows
for the visualization of defects in the cell wall which could be attributed to mutated
CpsA. Previous studies have shown that WT CpsA fluoresces just around the outside of
the cell wall, while ∆CpsA strains can be fully fluorescent. This difference is likely due
to lower cell wall integrity of ∆CpsA strains, which allows the cell walls to be leaky and
the stain to enter the entire cell. It is hypothesized that mutations in CpsA will cause a
decrease in cell wall integrity due to the proposed interactions of CpsA with protein
components associated with the cell wall.
A Western blot can be used to confirm if the protein is being displayed on the
outside of the cell. This allows for the confirmation of whether or not the protein is
actually making it to the membrane or not. In this experiment, the cell wall and cell
membrane would be separated from the cytoplasm, resulting in two fractions. An
antibody to the MBP protein, which is used to tag CpsA, would be used. If the CpsA
protein is located properly, it would appear in the membrane fraction, but not in the
cytoplasm fraction.
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Microinjection of zebrafish can be used to visualize the path of infection via
fluorescently tagged immune cells. This allows for the understanding of the function of
the accessory domain as a virulence factor of GBS. In these experiments, two types of
injections would occur. The first is a yolk sac injection, which would cause a systemic
infection and could be used to measure overall virulence of the strain. The second type of
injection that would occur is an otic vesicle injection, which would cause a localized
infection and can be used to determine the chemotaxis of neutrophils to the site of
infection. Previous research performed in the Neely lab suggests that 100% zebrafish
succumb to WT GBS infection by 72 hours post injection. The effect of mutant CpsA
injection can be compared to this data to determine if the mutant strain is more or less
virulent. It is hypothesized that mutated CpsA will decrease the amount of capsule on the
cell and will allow the immune system to recognize and clear the infection.
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